Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
Sunshine Biopharma (NASDAQ:SBFM) has secured marketing rights for two new generic antibiotics in Canada through a strategic agreement. The company plans to launch these products through its subsidiary, Nora Pharma, within six to nine months pending regulatory approval.
The global antibiotics market, valued at $53.9 billion in 2024, is projected to reach $85.8 billion by 2033, growing at a CAGR of 5.3%. North America and Europe collectively hold approximately 45% market share, with Canada representing about 2.2% ($1.2 billion) of the global market.
These new antibiotics will complement Nora Pharma's existing portfolio of 70 generic prescription drugs currently marketed in Canada.
Sunshine Biopharma (NASDAQ:SBFM) ha ottenuto i diritti di commercializzazione per due nuovi antibiotici generici in Canada tramite un accordo strategico. L'azienda prevede di lanciare questi prodotti attraverso la sua filiale, Nora Pharma, entro sei-nove mesi, in attesa dell'approvazione regolatoria.
Il mercato globale degli antibiotici, valutato 53,9 miliardi di dollari nel 2024, si prevede raggiunga 85,8 miliardi di dollari entro il 2033, con una crescita annuale composta (CAGR) del 5,3%. Il Nord America e l'Europa detengono collettivamente circa il 45% della quota di mercato, con il Canada che rappresenta circa il 2,2% (1,2 miliardi di dollari) del mercato globale.
Questi nuovi antibiotici completeranno il portafoglio esistente di Nora Pharma, che attualmente commercializza 70 farmaci generici con prescrizione in Canada.
Sunshine Biopharma (NASDAQ:SBFM) ha obtenido los derechos de comercialización para dos nuevos antibióticos genéricos en Canadá a través de un acuerdo estratégico. La empresa planea lanzar estos productos a través de su filial, Nora Pharma, en un plazo de seis a nueve meses, a la espera de la aprobación regulatoria.
El mercado global de antibióticos, valorado en 53,9 mil millones de dólares en 2024, se proyecta que alcanzará 85,8 mil millones de dólares para 2033, creciendo a una tasa compuesta anual (CAGR) del 5,3%. América del Norte y Europa en conjunto poseen aproximadamente el 45% de la cuota de mercado, con Canadá representando alrededor del 2,2% (1,2 mil millones de dólares) del mercado global.
Estos nuevos antibióticos complementarán el portafolio existente de Nora Pharma, que actualmente comercializa 70 medicamentos genéricos con receta en Canadá.
선샤인 바이오파마 (NASDAQ:SBFM)는 전략적 계약을 통해 캐나다에서 두 가지 새로운 일반 항생제에 대한 마케팅 권리를 확보했습니다. 이 회사는 규제 승인 대기 중에 자회사인 노라 파르마를 통해 이러한 제품을 6개월에서 9개월 이내에 출시할 계획입니다.
2024년 539억 달러로 평가된 글로벌 항생제 시장은 2033년까지 858억 달러에 이를 것으로 예상되며, 연평균 성장률(CAGR)은 5.3%입니다. 북미와 유럽은 총 시장 점유율의 약 45%를 차지하며, 캐나다는 전 세계 시장의 약 2.2% (12억 달러)를 차지하고 있습니다.
이 새로운 항생제는 현재 캐나다에서 판매되는 70개의 일반 처방약을 보유한 노라 파르마의 기존 포트폴리오를 보완할 것입니다.
Sunshine Biopharma (NASDAQ:SBFM) a obtenu les droits de commercialisation de deux nouveaux antibiotiques génériques au Canada grâce à un accord stratégique. L'entreprise prévoit de lancer ces produits par le biais de sa filiale, Nora Pharma, dans un délai de six à neuf mois, en attendant l'approbation réglementaire.
Le marché mondial des antibiotiques, évalué à 53,9 milliards de dollars en 2024, devrait atteindre 85,8 milliards de dollars d'ici 2033, avec un taux de croissance annuel composé (CAGR) de 5,3%. L'Amérique du Nord et l'Europe détiennent collectivement environ 45% de part de marché, le Canada représentant environ 2,2% (1,2 milliard de dollars) du marché mondial.
Ces nouveaux antibiotiques viendront compléter le portefeuille existant de Nora Pharma, qui commercialise actuellement 70 médicaments génériques sur ordonnance au Canada.
Sunshine Biopharma (NASDAQ:SBFM) hat sich die Vermarktungsrechte für zwei neue generische Antibiotika in Kanada durch eine strategische Vereinbarung gesichert. Das Unternehmen plant, diese Produkte über seine Tochtergesellschaft, Nora Pharma, innerhalb von sechs bis neun Monaten nach Erhalt der behördlichen Genehmigung auf den Markt zu bringen.
Der globale Antibiotikamarkt, der 2024 auf 53,9 Milliarden Dollar geschätzt wird, wird bis 2033 auf 85,8 Milliarden Dollar anwachsen und dabei eine jährliche Wachstumsrate (CAGR) von 5,3% erreichen. Nordamerika und Europa halten zusammen etwa 45% des Marktanteils, wobei Kanada etwa 2,2% (1,2 Milliarden Dollar) des globalen Marktes ausmacht.
Diese neuen Antibiotika werden das bestehende Portfolio von Nora Pharma ergänzen, das derzeit 70 generische verschreibungspflichtige Medikamente in Kanada vertreibt.
- Expansion into $1.2 billion Canadian antibiotics market
- Addition of two new products to existing portfolio of 70 generic drugs
- Strategic entry into growing market with 5.3% CAGR
- 6-9 month delay before product launch pending regulatory approval
FORT LAUDERDALE, FL / ACCESS Newswire / March 24, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that is has signed a strategic agreement granting it the rights to market two new generic antibiotics in Canada. The Company anticipates launching these new products through its wholly-owned Canadian subsidiary, Nora Pharma, in the next six to nine months following regulatory approval.
According to BioSpace, the global antibiotics market size in 2024 was estimated at
"We believe we are strategically positioned, through Nora Pharma, to introduce these two new antibiotics to the market, complementing our existing portfolio of 70 generic prescription drugs currently on the market in Canada. This expansion signifies a pivotal step in our mission to advance healthcare solutions for our patients," stated Dr. Steve Slilaty, CEO of Sunshine Biopharma.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancie sreceiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to regulatory approvals, the Company's drug development activities, financial performance, and future growth and product launches. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For Additional Information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
What new products did Sunshine Biopharma (SBFM) acquire rights for in March 2024?
When will SBFM launch the new antibiotics in Canada?
What is the size of the Canadian antibiotics market that SBFM is entering?
How many generic prescription drugs does SBFM currently market in Canada?
What is the projected growth rate of the global antibiotics market through 2033?
